Cooperative Agreement W81XWH1720004

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the execution of Investigational New Drug (IND)-enabling studies for an orally bioavailable small molecule PCSK9/LDLR antagonist (P-21) to treat hypercholesterolemia. The $3,685,958 award, effective September 1, 2024 through June 30, 2026, will fund critical preclinical studies, including dog dose range finding, GLP toxicology, safety...

Novelmed Therapeutics, Inc. was awarded a $1,599,495 Project Grant from the National Heart, Lung and Blood Institute of the Department of Health and Human Services. The grant falls under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. Novelmed will use the funding to develop a novel disease-modifying treatment for paroxysmal nocturnal hemoglobinuria (PNH). The company's lead drug candidate selectively inhibits the alternative pathway of...

This $299,504 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel therapeutic approach to clear small dense low-density lipoprotein (SDLDL) from circulation. The research aims to reengineer a proprietary APOC-III antagonist to include bioactive APOE mimetic peptides, creating a dual-domain therapeutic candidate that can bind APOC-III on SDLDL particles and...

The National Institutes of Health National Institute on Aging awarded Arviat Pharmaceuticals, Inc. a $1,350,180 Project Grant under the Aging Research program (CFDA 93.866) on September 30, 2021 to develop novel small-molecule inhibitors of the 12/15-lipoxygenase enzyme family. The goal is to reduce neuroinflammation and slow disease progression in Alzheimer's disease by inhibiting 12/15-LO activity. Under the award, Arviat will screen compounds from existing patent portfolios and develop...

This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of small molecule inhibitors of the LPXH enzyme as novel antibiotics for treating multidrug-resistant Enterobacterales infections. The goal is to design and synthesize potent LPXH inhibitors with optimal drug-like properties, and to demonstrate the safety and efficacy of a lead LPXH...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded Revidia Therapeutics, Inc. a $1,358,179 Project Grant to conduct IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436. This novel therapy aims to treat fatal cardiomyopathy in patients with Duchenne muscular dystrophy (DMD), a leading cause of mortality in this population. The proposed studies will...

This Project Grant award of $401,566.00 from the National Center for Advancing Translational Sciences (CFDA 93.350) to The Trustees of the University of Pennsylvania aims to advance research on LCAT deficiency, an ultra-rare genetic disorder. The key objectives are to: 1) Identify biomarkers to guide patient enrollment and monitor efficacy for potential treatments, including distinguishing between the two LCAT deficiency syndromes (Familial LCAT Deficiency and Fish-Eye Disease); 2) Determine...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Parmedics, Inc., a for-profit, woman-owned biotechnology company, for the development of small molecule protease-activated receptor-2 (PAR2) antagonists as potential oral therapeutics for asthma. The goal is to characterize two novel PAR2 antagonists, C937 and C938, with improved pharmacodynamics and pharmacokinetics to enable...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel drug candidate to treat idiopathic pulmonary fibrosis (IPF). The award of $356,250 will support a two-phase project by Vasarya Therapeutics, Inc. to perform affinity maturation and liability assessment on a tool compound called VSR-H5, which has demonstrated the ability to selectively target and inhibit...